Immuno Oncology Assays Market | Growth, Industry Trends Insights
The Asia Pacific is projected to record the highest growth rate in immuno oncology assays market. Factors such as growing number of CROs in the region, increasing awareness about early detection of cancer, and the shift of manufacturers’ and suppliers’ focus from developed economies to emerging economies, such as India and China are driving the growth of this regional segment.
1 In 2018, Roche collaborated with SQZ Biotech to develop antigen presenting cells-based immune-oncology treatments.
2 In 2018, Illumina launched its TruSight Oncology 500 assay, which is used to identify known and emerging tumor biomarkers.
3 In 2018, Roche acquired Tusk Therapeutics to expand its oncology product portfolio.
4 In 2018, Agilent acquired ACEA Biosciences (US). This acquisition will help both the companies to focus on real-time, live-cell analyzes through their expertise in cellular function and metabolism measurements.
5 In 2016, Thermo Fisher collaborated with Invivoscribe Technologies to develop NGS-based in vitro diagnostic oncology tests.
We just sent you an email. Please click the link in the email to confirm your subscription!
OKSubscriptions powered by Strikingly